Page 177 - 2019_10 resto del Mondo_web

HDAC + MEK or BCL-2 inhibition in multiple myeloma
other HDAC1/2-containing complexes could achieve greater efficacy with potentially less toxicity.50
Acknowledgments
We thank Dr. Scott Kaufmann, M.D., Ph.D. for helpful dis- cussions and commentary during the writing of this manuscript. We also thank the patients and their families for the gracious donation of their bone marrow aspirates to our laboratory. This work was funded by the Predolin Foundation, Mayo Clinic Hematology Small Grants Program, International Myeloma
Foundation, CTSA grant number TL1TR002380 from the National Center for Advancing Translational Sciences (NCATS), Mayo Clinic Multiple Myeloma SPORE, Wendy Will Case Cancer Fund, Mayo Clinic Development Funds from the Myeloma, Amyloidosis and Dysproteinemia Disease Oriented Group (MADDOG), and the Mayo Clinic Office of Translation to Practice. Additionally, we would like to thank the American Association for Cancer Research for a Scholar-in- Training Award, and the American Society of Hematology for an HONORS award.
References
1. Rajkumar SV. Treatment of multiple myelo- ma. Nat Rev Clin Oncol. 2011;8(8):479-491.
2. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med.
2006;354(13):1362-1369.
3. Noone AM, Howlader N, Krapcho M, et al.
SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data sub- mission, posted to the SEER web site, April 2018.
4. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in mul- tiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-1128.
5. SonneveldP,Avet-LoiseauH,LonialS,etal. Treatment of multiple myeloma with high- risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-2962.
6. Kumar SK, Rajkumar SV. The multiple myelomas — current concepts in cytogenet- ic classification and therapy. Nat Rev Clin Oncol. 2018;15(7):409-421.
7. Chng WJ, Gonzalez-Paz N, Price-Troska T, et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia. 2008;22(12):2280-2284.
8. Lentzsch S, Chatterjee M, Gries M, et al. PI3-K/AKT/FKHR and MAPK signaling cas- cades are redundantly stimulated by a vari- ety of cytokines and contribute independ- ently to proliferation and survival of multi- ple myeloma cells. Leukemia. 2004;18(11): 1883-1890.
9. Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequenc- ing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911- 3920.
10. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM. Possible roles for activating RAS mutations in the MGUS to MM transi- tion and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood. 2005;105(1):317-323.
11. Kortüm KM, Mai EK, Hanafiah NH, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016;128(9):1226-1233.
12. RamakrishnanV,D'SouzaA.Signalingpath- ways and emerging therapies in multiple myeloma. Curr Hematol Malig Rep. 2016;11(2):156-164.
13. Holkova B, Zingone A, Kmieciak M, et al. A phase 2 trial of AZD6244 (selumetinib, ARRY-142886), an oral MEK1/2 inhibitor, in relapsed/refractory multiple myeloma. Clin Cancer Res. 2016;22(5):1067-1075.
14. West AC, Johnstone RW. New and emerg- ing HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124(1):30-39.
15. Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Panobinostat for the treat- ment of multiple myeloma. Clin Cancer Res. 2015;21(21):4767-4773.
16. Meng J, Fang B, Liao Y, Chresta CM, Smith PD, Roth JA. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS One. 2010;5(9):e13026.
17. Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, Hersey P. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res. 2007;13(16): 4934-4942.
18. Chen S, Dai Y, Pei XY, Grant S. Bim upregu- lation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antago- nist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Bio. 2009;29(23):6149-6169.
19. Ramakrishnan V, Kimlinger T, Timm M, Haug J, Rajkumar SV, Kumar S. Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapa- log RAD001. Leuk Res. 2014;38(11):1358- 1366.
20. Correia C, Lee S-H, Meng XW, et al. Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochim Biophys Acta. 2015; 1853(7):1658-1671.
21. Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11): 2443-2448.
22. Ramakrishnan V, Ansell S, Haug J, et al. MRK003, a g-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lym- phoma. Leukemia. 2012;26(2):340-348.
23. Kumar S, Raje N, Hideshima T, et al. Antimyeloma activity of two novel N-sub- stituted and tetraflourinated thalidomide analogs. Leukemia. 2005;19(7):1253-1261.
24. Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27- 55.
25. Ghobrial IM, Detappe A, Anderson KC,
Steensma DP. The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat Rev Clin Oncol. 2018;15(4):219- 233.
26. Cragg MS, Jansen ES, Cook M, et al. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest. 2008;118(11):3651-3659.
27. Dai H, Ding H, Meng XW, Lee SH, Schneider PA, Kaufmann SH. Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. Cancer Res. 2013;73(23): 6998-7008.
28. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004;23(31):5301-5315.
29. Kobayashi S, Lee S-H, Meng XW, et al. Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem. 2007;282(25):18407-18417.
30. Choudhary GS, Tat TT, Misra S, et al. Cyclin E/Cdk2-dependent phosphorylation of Mcl- 1 determines its stability and cellular sensi- tivity to BH3 mimetics. Oncotarget. 2015;6(19):16912-16925.
31. Yee AJ, Bensinger WI, Supko JG, et al. Ricolinostat plus lenalidomide, and dexame- thasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncol. 2016;17(11):1569-1578.
32. Tatamiya T, Saito A, Sugawara T, Nakanishi O. Isozyme-selective activity of the HDAC inhibitor MS-275. Cancer Res. 2004;64(7):567.
33. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 2018;173(2):321-37.e10.
34. Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 2014;11(7):385-400.
35. Mulligan, G, Lichter, DI, Di Bacco, A, et al. Mutation of NRAS but not KRAS signifi- cantly reduces myeloma sensitivity to sin- gle-agent bortezomib therapy. Blood. 2004;123(5):632-639.
36. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004;23(31):5301-5315.
37. Wuilleme-Toumi S, Robillard N, Gomez P, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005;19(7):1248- 1252.
38. Gores GJ, Kaufmann SH. Selectively target- ing Mcl-1 for the treatment of acute myel-
haematologica | 2019; 104(10)
2073